Invasive aspergillosis is a common cause of morbidity and mortality in hematopoietic stem cell transplant recipients, 15% according to published data, patients with acquired or congenital aplastic anemia may be colonized previously to conditioning. We retrospectively evaluate the occurrence of invasive aspergillosis in transplanted patients with Fanconi Anemia between 2007- 2014. 12 patients, 4 males and 8 females, median age 8 years (6-11), 5 patients received bone marrow from matched sibling donor (MSD) and 7 patients received unrelated cord blood (UCB), conditioning was fludarabine based without radiation in all cases, antifungal profilaxis with fluconazol for MDS and voriconazole for UCB. 3 patients (25%) developed proven pulmonary aspergillosis and requiered surgery and antifungal therapy with voriconazol (1 patient) and combination therapy with voriconazol and caspofungine (2 patients), all three cases received treatment for acute or chronic graft vs host disease, one patient died decause of bacterial sepsis, the other two patients are well and alive. Compared with other diagnosis Fanconi Anemia represent a very high risk group for proven aspergillosis during transplantation, in our cohort (25%) despite voriconazol profilaxis. New considerations for prevention of invasive aspergillosis (new antifungal drus, pretransplant diagnosis) must be evaluated in this group of patients.